Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Embecta Corporation ( (EMBC) ) is now available.
On May 15, 2026, Embecta completed its acquisition of Owen Mumford Holdings Limited, following a March 19, 2026 purchase agreement with the sellers. Embecta paid £100 million in upfront cash, subject to customary closing adjustments, and may pay up to an additional £50 million tied to commercial milestones for net sales of the Aidaptus auto-injector platform through June 30, 2029.
The deal is intended to speed Embecta’s transformation into a broad-based medical supplies company supplying drug delivery platforms to pharmaceutical clients and chronic care patients in areas such as obesity, diabetes, autoimmune diseases and anaphylaxis. By combining Owen Mumford’s device design and manufacturing capabilities with Embecta’s global commercial network and large-scale production, the acquisition enhances Embecta’s intellectual property portfolio, broadens its chronic care device offerings and is expected to create geographic expansion and operational efficiencies for stakeholders.
The most recent analyst rating on (EMBC) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Embecta Corporation stock, see the EMBC Stock Forecast page.
Spark’s Take on EMBC Stock
According to Spark, TipRanks’ AI Analyst, EMBC is a Neutral.
Overall score is weighed down primarily by stressed financial structure (high leverage/negative equity) and very bearish technicals. The latest earnings call further pressured the outlook due to major guidance cuts and U.S. share-loss-driven declines, only partly offset by solid recent cash generation and longer-term strategic diversification efforts.
To see Spark’s full report on EMBC stock, click here.
More about Embecta Corporation
Embecta Corp., listed on Nasdaq as EMBC, is a global diabetes care technology company that is evolving from its 100‑year legacy in insulin delivery into a broad-based medical supplies provider. With about 2,500 employees worldwide, it develops and distributes drug delivery platforms and chronic care devices that support patients with long-term conditions.
Owen Mumford, founded in 1952 and headquartered in Oxfordshire in the U.K., is a medical technology firm specializing in drug delivery systems and chronic care and point-of-care devices. It is recognized as a partner to pharmaceutical and biotechnology companies, notably through its Aidaptus auto-injector platform for complex therapies and self-injection solutions sold globally.
Average Trading Volume: 1,579,385
Technical Sentiment Signal: Sell
Current Market Cap: $186.3M
For an in-depth examination of EMBC stock, go to TipRanks’ Overview page.